Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Background Blood pressure reduction achieved with beta-blockers and diuretics is the best recorded intervention to date for prevention of cardiovascular morbidity and death in patients with hypertension. Left ventricular hypertrophy (LVH) is a strong independent indicator of risk of cardiovascular morbidity and death. We aimed to establish whether selective blocking of angiotensin II improves LVH beyond reducing blood pressure and, consequently, reduces cardiovascular morbidity and death. Methods We did a double-masked, randomised, parallel-group trial in 9193 participants aged 55-80 years with essential hypertension (sitting blood pressure 160-200/95-115 mm Hg) and LVH ascertained by electrocardiography (ECG). We assigned participants once daily losartan-based or atenolol-based antihypertensive treatment for at least 4 years and until 1040 patients had a primary cardiovascular event (death, myocardial infarction, or stroke). We used Cox regression analysis to compare regimens. Findings Blood pressure fell by 30.2/16.6 (SD 18.5/10.1) and 29.1/16.8 mm Hg (19.2/10.1) in the losartan and atenolol groups, respectively. The primary composite endpoint occurred in 508 losartan (23.8 per 1000 patient-years) and 588 atenolol patients (27.9 per 1000 patient-years; relative risk 0.87, 95% CI 0.77-0.98, p=0.021). 204 losartan and 234 atenolol patients died from cardiovascular disease (0.89, 0.73-1.07, p=0.206); 232 and 309, respectively, had fatal or non-fatal stroke (0.75, 0.63-0.89, p=…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“an 11% reduction in myocardial infarction (MI)”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
In the citing paper
“This study showed that each 10 mm Hg decrease in systolic BP (achieved with either an ACE inhibitor [captopril] or a beta blocker [atenolol]) was associated with a 15% reduction in DM-related mortality”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
In the citing paper
“and a 13% reduction in the microvascular complications of retinopathy or DKD.186”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
In the citing paper
“Clinical trial data show that intensifying therapy with BP-lowering medications slows the progression of DKD and retinopathy, though vigilance in monitoring renal function during intensive BP therapy is recommended.185,186,201–203”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
In the citing paper
“Optimization of glucose and BP are the proven strategies for primary prevention of diabetic retinopathy and for slowing the progression of preexisting nonproliferative retinopathy.78,185,186,193,522,523”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Hansson, L., Lindholm, L. H., Niskanen, L., Lanke, J., Hedner, T., Niklason, A., Luomanmäki, K., Dahlöf, B., de Faire, U., Mörlin, C., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)05012-0 · Cited by 2,014
Self-citationMorbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)
Dahlöf, B., Hansson, L., Lindholm, L. H., Scherstén, B., Ekbom, T., & Wester, P.-O. (1991) · The Lancet · doi:10.1016/0140-6736(91)92589-t · Cited by 1,881
Self-citationAn updated coronary risk profile. A statement for health professionals.
Anderson, K. M., Wilson, P. W., Odell, P. M., & Kannel, W. B. (1991) · Circulation · doi:10.1161/01.cir.83.1.356 · Cited by 1,834
The Norwegian Multicenter Study Group (1981) · New England Journal of Medicine · doi:10.1056/nejm198104023041401 · Cited by 1,675
Hansson, L., Lindholm, L. H., Ekbom, T., Dahlöf, B., Lanke, J., Scherstén, B., Wester, P.-O., Hedner, T., & de Faire, U. (1999) · The Lancet · doi:10.1016/s0140-6736(99)10327-1 · Cited by 1,447
Self-citationReversal of Left Ventricular Hypertrophy in Hypertensive Patients
Dahlöf, B., Pennert, K., & Hansson, L. (1992) · American Journal of Hypertension · doi:10.1093/ajh/5.2.95 · Cited by 925
Self-citationLemon, D. (1987) · The Journal of Emergency Medicine · doi:10.1016/0736-4679(87)90192-2 · Cited by 563
Research works printed but not linked: 2
- Dhlöf, 1997, The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension Study: rationale, design, and methods, Am J Hypertens, 10, 705
- Mulrow, 2001, Pharmacotherapy for hypertension in the elderly (Cochrane review)
Cited by
Items 201–300 of 1,018
Left ventricular hypertrophy and hypertension
Yildiz, M., Oktay, A. A., Stewart, M. H., Milani, R. V., Ventura, H. O., & Lavie, C. J. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.11.009 · Cited by 333
Sarafidis, P. A., & Bakris, G. L. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.08.036 · Cited by 332
Effect of different antihypertensive drug classes on central aortic pressure
Morgan, T. (2004) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2003.09.012 · Cited by 330
SCHIFFRIN, E. (2004) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2004.05.023 · Cited by 327
London, G. M., Asmar, R. G., O'Rourke, M. F., & Safar, M. E. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.07.039 · Cited by 325
Cardiac and vascular pathophysiology in hypertension
Mayet, J., & Hughes, A. (2003) · Heart · doi:10.1136/heart.89.9.1104 · Cited by 321
Gender differences in the effects of cardiovascular drugs
Tamargo, J., Rosano, G., Walther, T., Duarte, J., Niessner, A., Kaski, J., Ceconi, C., Drexel, H., Kjeldsen, K., Savarese, G., et al. (2017) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw042 · Cited by 317
Avolio, A. P., Butlin, M., & Walsh, A. (2010) · Physiological Measurement · doi:10.1088/0967-3334/31/1/r01 · Cited by 310
Lindholm, L. H., Persson, M., Alaupovic, P., Carlberg, B., Svensson, A., & Samuelsson, O. G. (2003) · PubMed · doi:10.1097/01.hjh.0000084723.53355.76 · Cited by 308
Self-citationType 2 Diabetes Mellitus and Hypertension
Lastra, G., Syed, S., Kurukulasuriya, L. R., Manrique, C., & Sowers, J. R. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.09.005 · Cited by 307
Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored
McMurray, J. J. V., Gerstein, H. C., Holman, R. R., & Pfeffer, M. A. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70031-2 · Cited by 304
Solomon, S. D., Appelbaum, E., Manning, W. J., Verma, A., Berglund, T., Lukashevich, V., Cherif Papst, C., Smith, B. A., & Dahlöf, B. (2009) · Circulation · doi:10.1161/circulationaha.108.826214 · Cited by 301
Self-citationI Diretriz Brasileira de Diagnóstico e Tratamento da Síndrome Metabólica
(2005) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2005000700001 · Cited by 299
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2019) · Endocrine Practice · doi:10.4158/cs-2018-0535 · Cited by 297
High Central Pulse Pressure Is Independently Associated With Adverse Cardiovascular Outcome
Roman, M. J., Devereux, R. B., Kizer, J. R., Okin, P. M., Lee, E. T., Wang, W., Umans, J. G., Calhoun, D., & Howard, B. V. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.05.070 · Cited by 295
Self-citationPrevention of Type 2 Diabetes Mellitus Through Inhibition of the Renin-Angiotensin System
Scheen, A. J. (2004) · Drugs · doi:10.2165/00003495-200464220-00004 · Cited by 293
Why blockade of the renin–angiotensin system reduces the incidence of new-onset diabetes
Jandeleit-Dahm, K. A., Tikellis, C., Reid, C. M., Johnston, C. I., & Cooper, M. E. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000160198.05416.72 · Cited by 293
Blood Pressure and Stroke: An Overview of Published Reviews
Lawes, C. M. M., Bennett, D. A., Feigin, V. L., & Rodgers, A. (2004) · Stroke · doi:10.1161/01.str.0000126208.14181.dd · Cited by 293
Bangalore, S., Parkar, S., Grossman, E., & Messerli, F. H. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.05.057 · Cited by 290
NON‐CORONARY HEART DISEASE IN DIALYSIS PATIENTS: Sudden Cardiac Death and Dialysis Patients
Herzog, C. A., Mangrum, J. M., & Passman, R. (2008) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2008.00455.x · Cited by 290
Pulse wave analysis and pulse wave velocity: a critical review of their strengths and weaknesses
Davies, J. I., & Struthers, A. D. (2003) · Journal of Hypertension · doi:10.1097/00004872-200303000-00004 · Cited by 289
Wolf, G., & Ritz, E. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00145.x · Cited by 289
Burroughs, V. J., Maxey, R. W., & Levy, R. A. (2002) · PubMed Central · Cited by 289
Cooper, C. J., Murphy, T. P., Matsumoto, A., Steffes, M., Cohen, D. J., Jaff, M., Kuntz, R., Jamerson, K., Reid, D., Rosenfield, K., et al. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.09.011 · Cited by 287
Surrogate Markers for Cardiovascular Disease: Functional Markers
Cohn, J. N., Quyyumi, A. A., Hollenberg, N. K., & Jamerson, K. A. (2004) · Circulation · doi:10.1161/01.cir.0000133442.99186.39 · Cited by 284
Angiotensin Blockade Prevents Type 2 Diabetes by Formation of Fat Cells
Sharma, A. M., Janke, J., Gorzelniak, K., Engeli, S., & Luft, F. C. (2002) · Hypertension · doi:10.1161/01.hyp.0000036448.44066.53 · Cited by 283
Graham, I., Atar, D., Borch-Johnsen, K., Boysen, G., Burell, G., Cifkova, R., Dallongeville, J., Backer, G. D., Ebrahim, S., Gjelsvik, B., et al. (2007) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/01.hjr.0000277984.31558.c4 · Cited by 281
Cheng, J., Zhang, W., Zhang, X., Han, F., Li, X., He, X., Li, Q., & Chen, J. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.348 · Cited by 280
Resistant Hypertension, Obesity, Sleep Apnea, and Aldosterone: Theory and Therapy
Goodfriend, T. L., & Calhoun, D. A. (2004) · Hypertension · doi:10.1161/01.hyp.0000116223.97436.e5 · Cited by 279
Koh, K. K., Quon, M. J., Han, S. H., Chung, W.-J., Ahn, J. Y., Seo, Y.-H., Kang, M. H., Ahn, T. H., Choi, I. S., & Shin, E. K. (2004) · Circulation · doi:10.1161/01.cir.0000143085.86697.13 · Cited by 279
Apparent and true resistant hypertension: definition, prevalence and outcomes
Judd, E., & Calhoun, D. A. (2014) · Journal of Human Hypertension · doi:10.1038/jhh.2013.140 · Cited by 277
Heinze, G., Mitterbauer, C., Regele, H., Kramar, R., Winkelmayer, W. C., Curhan, G. C., & Oberbauer, R. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005090955 · Cited by 276
Vascular Remodeling in Hypertension: Mechanisms and Treatment
Schiffrin, E. L. (2012) · Hypertension · doi:10.1161/hypertensionaha.111.187021 · Cited by 276
Inflammation and Infection in Clinical Stroke
Emsley, H. C. A., & Tyrrell, P. J. (2002) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200212000-00001 · Cited by 276
Reboldi, G., Gentile, G., Angeli, F., Ambrosio, G., Mancia, G., & Verdecchia, P. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283469976 · Cited by 275
Schupp, M., Clemenz, M., Gineste, R., Witt, H., Janke, J., Helleboid, S., Hennuyer, N., Ruiz, P., Unger, T., Staels, B., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3442 · Cited by 274
Soltani, Z., Rasheed, K., Kapusta, D. R., & Reisin, E. (2013) · Current Hypertension Reports · doi:10.1007/s11906-013-0344-5 · Cited by 272
Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases
Jochmann, N., Stangl, K., Garbe, E., Baumann, G., & Stangl, V. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi397 · Cited by 272
Charytan, D., & Kuntz, R. E. (2006) · Kidney International · doi:10.1038/sj.ki.5001934 · Cited by 271
Okin, P. M., Wachtell, K., Devereux, R. B., Harris, K. E., Jern, S., Kjeldsen, S. E., Julius, S., Lindholm, L. H., Nieminen, M. S., Edelman, J. M., et al. (2006) · JAMA · doi:10.1001/jama.296.10.1242 · Cited by 270
Self-citationKaul, S., & Diamond, G. A. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.06.065 · Cited by 269
Molecular Mechanisms of Insulin Resistance That Impact Cardiovascular Biology
Wang, C. C. L., Goalstone, M. L., & Draznin, B. (2004) · Diabetes · doi:10.2337/diabetes.53.11.2735 · Cited by 268
Lindholm, L. H., Persson, M., Alaupovic, P., Carlberg, B., Svensson, A., & Samuelsson, O. (2003) · Journal of Hypertension · doi:10.1097/00004872-200308000-00022 · Cited by 266
Self-citationSystolic and diastolic blood pressure control in antihypertensive drug trials
Mancia, G., & Grassi, G. (2002) · Journal of Hypertension · doi:10.1097/00004872-200208000-00001 · Cited by 266
Chrysant, S. G., Melino, M., Karki, S., Lee, J., & Heyrman, R. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.04.002 · Cited by 266
Angiotensin AT2 receptor protects against cerebral ischemia‐induced neuronal injury
Li, J., Culman, J., Hörtnagl, H., Zhao, Y., Gerova, N., Timm, M., Blume, A., Zimmermann, M., Seidel, K., Dirnagl, U., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-2960fje · Cited by 266
Nelson, M. R., Stepanek, J., Cevette, M., Covalciuc, M., Hurst, R. T., & Tajik, A. J. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0336 · Cited by 264
Bahlmann, F. H., de Groot, K., Mueller, O., Hertel, B., Haller, H., & Fliser, D. (2005) · Hypertension · doi:10.1161/01.hyp.0000159191.98140.89 · Cited by 259
Lionakis, N. (2012) · World Journal of Cardiology · doi:10.4330/wjc.v4.i5.135 · Cited by 258
Left Ventricular Hypertrophy and Clinical Outcomes in Hypertensive Patients
Ruilope, L. M., & Schmieder, R. E. (2008) · American Journal of Hypertension · doi:10.1038/ajh.2008.16 · Cited by 258
Clinical Pharmacokinetics of Losartan
Sica, D. A., Gehr, T. W. B., & Ghosh, S. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544080-00003 · Cited by 258
Okin, P. M., Devereux, R. B., Jern, S., Kjeldsen, S. E., Julius, S., Nieminen, M. S., Snapinn, S., Harris, K. E., Aurup, P., Edelman, J. M., et al. (2003) · Circulation · doi:10.1161/01.cir.0000083724.28630.c3 · Cited by 257
Self-citationThe AT2 receptor—A matter of love and hate
Steckelings, U. M., Kaschina, E., & Unger, T. (2005) · Peptides · doi:10.1016/j.peptides.2005.03.010 · Cited by 257
Bakris, G. L., Fonseca, V., & Katholi, R. L. (2005) · ACC Current Journal Review · doi:10.1016/j.accreview.2004.12.136 · Cited by 256
The renin–angiotensin system and diabetes: An update
Silva, A. C. S. E. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s1905 · Cited by 255
The role of oxidative stress in atherosclerosis.
Vogiatzi, G., Tousoulis, D., & Stefanadis, C. (2009) · PubMed · Cited by 254
Schiffrin, E. L., & Touyz, R. M. (2004) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00262.2004 · Cited by 253
Renin-angiotensin system inhibition prevents type 2 diabetes mellitus
Scheen, A. (2004) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70146-5 · Cited by 252
Lymphocyte responses exacerbate angiotensin II-dependent hypertension
Crowley, S. D., Song, Y.-S., Lin, E. E., Griffiths, R., Kim, H.-S., & Ruiz, P. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00373.2009 · Cited by 252
Possible Inhibition of Focal Cerebral Ischemia by Angiotensin II Type 2 Receptor Stimulation
Iwai, M., Liu, H.-W., Chen, R., Ide, A., Okamoto, S., Hata, R., Sakanaka, M., Shiuchi, T., & Horiuchi, M. (2004) · Circulation · doi:10.1161/01.cir.0000138848.58269.80 · Cited by 252
Kamat, A. M., Flaig, T. W., Grossman, H. B., Konety, B., Lamm, D., O'Donnell, M. A., Uchio, E., Efstathiou, J. A., & Taylor, J. A. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.58 · Cited by 252
Turnbull, F., Woodward, M., Neal, B., Barzi, F., Ninomiya, T., Chalmers, J., Perkovic, V., Li, N., MacMahon, S., & the Blood Pressure Lowering Treatment Trialists' Collaboration (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn427 · Cited by 252
Strauss, M. H., & Hall, A. S. (2006) · Circulation · doi:10.1161/circulationaha.105.594986 · Cited by 249
Insulin Resistance as the Underlying Cause for the Metabolic Syndrome
Lann, D., & LeRoith, D. (2007) · Medical Clinics of North America · doi:10.1016/j.mcna.2007.06.012 · Cited by 249
Adiponectin, Cardiovascular Function, and Hypertension
Wang, Z. V., & Scherer, P. E. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.099424 · Cited by 247
STAESSEN, J. A., LI, Y., THIJS, L., & WANG, J.-G. (2005) · Hypertension Research · doi:10.1291/hypres.28.385 · Cited by 247
Khan, N. A., Hemmelgarn, B., Padwal, R., Larochelle, P., Mahon, J. L., Lewanczuk, R. Z., McAlister, F. A., Rabkin, S. W., Hill, M. D., Feldman, R. D., et al. (2007) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(07)70798-5 · Cited by 246
Caldeira, D., Alarcao, J., Vaz-Carneiro, A., & Costa, J. (2012) · BMJ · doi:10.1136/bmj.e4260 · Cited by 246
A major health hazard: The metabolic syndrome
Isomaa, B. (2003) · Life Sciences · doi:10.1016/s0024-3205(03)00646-5 · Cited by 245
McFarlane, S. I., Kumar, A., & Sowers, J. R. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00432-6 · Cited by 245
Wachtell, K., Hornestam, B., Lehto, M., Slotwiner, D. J., Gerdts, E., Olsen, M. H., Aurup, P., Dahlöf, B., Ibsen, H., Julius, S., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.06.080 · Cited by 243
Self-citationOgihara, T., Nakao, K., Fukui, T., Fukiyama, K., Ueshima, K., Oba, K., Sato, T., & Saruta, T. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.098475 · Cited by 242
Westphal, M., Ylä-Herttuala, S., Martin, J., Warnke, P., Menei, P., Eckland, D., Kinley, J., Kay, R., & Ram, Z. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70274-2 · Cited by 241
Howard, B. V. (2008) · JAMA · doi:10.1001/jama.299.14.1678 · Cited by 241
Self-citationBrewster, U. C., Perazella, M. A., & Setaro, J. F. (2003) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200307000-00003 · Cited by 241
Ferrario, C. M. (2006) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.3317/jraas.2006.003 · Cited by 240
Angiotensin-(1–7): beyond the cardio-renal actions
Passos-Silva, D. G., Verano-Braga, T., & Santos, R. A. S. (2013) · Clinical Science · doi:10.1042/cs20120461 · Cited by 240
Brown, A. J. M., Gandy, S., McCrimmon, R., Houston, J. G., Struthers, A. D., & Lang, C. C. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa419 · Cited by 239
AT2 receptors: Functional relevance in cardiovascular disease
Jones, E. S., Vinh, A., McCarthy, C. A., Gaspari, T. A., & Widdop, R. E. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.08.009 · Cited by 237
Arterial Stiffness and Stroke in Hypertension: Therapeutic Implications for Stroke Prevention
Laurent, S., & Boutouyrie, P. (2005) · CNS Drugs · doi:10.2165/00023210-200519010-00001 · Cited by 236
Cardiovascular Protection Using Beta-Blockers
Bangalore, S., Messerli, F. H., Kostis, J. B., & Pepine, C. J. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.04.060 · Cited by 233
Nonallergic angioedema: role of bradykinin
Bas, M., Adams, V., Suvorava, T., Niehues, T., Hoffmann, T. K., & Kojda, G. (2007) · Allergy · doi:10.1111/j.1398-9995.2007.01427.x · Cited by 232
Uric acid: role in cardiovascular disease and effects of losartan
Alderman, M., & Aiyer, K. J. V. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125002982 · Cited by 231
Disorders of Hemostasis Associated with Chronic Kidney Disease
Jalal, D., Chonchol, M., & Targher, G. (2010) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0030-1248722 · Cited by 231
Lau, T., Carlsson, P.-O., & Leung, P. S. (2004) · Diabetologia · doi:10.1007/s00125-003-1295-1 · Cited by 230
Combination therapy in hypertension
Gradman, A. H., Basile, J. N., Carter, B. L., & Bakris, G. L. (2010) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2010.02.005 · Cited by 230
Insulin resistance and the endothelium
Hsueh, W. A., Lyon, C. J., & Quiñones, M. J. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.02.042 · Cited by 229
Norris, S. L., Kansagara, D., Bougatsos, C., & Fu, R. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-11-200806030-00008 · Cited by 228
Capítulo 1 - Conceituação, Epidemiologia e Prevenção Primária
Malachias, M. V. B., Souza, W., Plavnik, F. L., Rodrigues, C., Brandão, A., Neves, M. F., Bortolotto, L. A., Franco, R., Figueiredo, C., Jardim, P., et al. (2016) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20160151 · Cited by 229
Diabetes, left ventricular systolic dysfunction, and chronic heart failure
MacDonald, M. R., Petrie, M. C., Hawkins, N. M., Petrie, J. R., Fisher, M., McKelvie, R., Aguilar, D., Krum, H., & McMurray, J. J. V. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn156 · Cited by 227
Angiotensin II and the Endothelium: Diverse Signals and Effects
Watanabe, T., Barker, T. A., & Berk, B. C. (2005) · Hypertension · doi:10.1161/01.hyp.0000153321.13792.b9 · Cited by 227
Wachtell, K., Okin, P. M., Olsen, M. H., Dahlöf, B., Devereux, R. B., Ibsen, H., Kjeldsen, S. E., Lindholm, L. H., Nieminen, M. S., & Thygesen, K. (2007) · Circulation · doi:10.1161/circulationaha.106.666594 · Cited by 226
Self-citationGender-specific care of the patient with diabetes: review and recommendations
Legato, M. J., Gelzer, A., Goland, R., Ebner, S. A., Rajan, S., Villagra, V., & Kosowski, M. (2006) · Gender Medicine · doi:10.1016/s1550-8579(06)80202-0 · Cited by 225
Differential effects of calcium antagonist subclasses on markers of nephropathy progression
Bakris, G. L., Weir, M. R., Secic, M., Campbell, B., & Weis-McNulty, A. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00620.x · Cited by 225
Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients
Koh, K. K., Ahn, J. Y., Han, S. H., Kim, D. S., Jin, D. K., Kim, H. S., Shin, M.-S., Ahn, T. H., Choi, I. S., & Shin, E. K. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00846-5 · Cited by 225
Manrique, C., Lastra, G., Gardner, M., & Sowers, J. R. (2009) · Medical Clinics of North America · doi:10.1016/j.mcna.2009.02.014 · Cited by 224
Winer, N., & Sowers, J. R. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004263017 · Cited by 223
Matsumoto, Y., Mori, Y., Kageyama, S., Arihara, K., Sugiyama, T., Ohmura, H., Yakushigawa, T., Sugiyama, H., Shimada, Y., Nojima, Y., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.09.056 · Cited by 223
Management of Gout and Hyperuricemia in CKD
Vargas-Santos, A. B., & Neogi, T. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.01.055 · Cited by 223
Relation of Beta-Blocker–Induced Heart Rate Lowering and Cardioprotection in Hypertension
Bangalore, S., Sawhney, S., & Messerli, F. H. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.06.048 · Cited by 222
Metadata
- Authors
- Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., Lindholm, L. H., Nieminen, M. S., Omvik, P., Oparil, S., & Wedel, H.
- Affiliations
- Sahlgrenska University Hospital (SE)
- Oslo University Hospital (NO)
- University of Michigan (US)
- Birmingham City Hospital (GB)
- Helsinki University Hospital (FI)
- Glostrup Hospital (DK)
- Umeå University (SE)
- Haukeland University Hospital (NO)
- University of Alabama at Birmingham (US)
- Nordic School of Public Health (SE)
- Corresponding author
- Dahlöf, Björn
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2002-03
- Volume
- 359
- Issue
- 9311
- Pages
- 995-1003
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2133217116
- Cited by
- 5,407
- References
- 29
- Citations by year
- 2026: 37 · 2025: 51 · 2024: 51 · 2023: 69 · 2022: 63 · 2021: 75 · 2020: 74 · 2019: 82 · 2018: 106 · 2017: 144 · 2016: 131 · 2015: 152 · 2014: 208 · 2013: 200 · 2012: 265
- FWCI
- 333.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
- Keywords
- atenolol, essential hypertension, left ventricular hypertrophy, angiotensin receptor blockers, beta-blockers, cardiovascular morbidity, cardiovascular mortality, stroke, myocardial infarction, blood pressure reduction, new-onset diabetes, antihypertensive therapy, elderly patients, secondary prevention of cardiovascular disease, renin-angiotensin system blockade
- MeSH terms
- Aged, Aged, 80 and over, Antihypertensive Agents, Atenolol, Cardiovascular Diseases, Double-Blind Method, Female, Humans, Hypertension, Male, Middle Aged, Losartan, Diabetes Complications, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.